Información
para Profesionales
para Profesionales
raffo > profesionales
Material de lectura Últimas publicaciones para profesionales
Vacunas 25 / 11 / 2022
Refuerzos Vacunas COVID-19: ¿Cómo informar a tus pacientes?
¿Cómo sigue el esquema de vacunación?
Si ya pasaron 4 meses desde la aplicación de  la última dosis, la información que hay que tener en cuenta es esta: Personas entre 3 y 17 años: Correspon [...]
Vacunas 15 / 11 / 2022
A Bivalent Omicron-Containing Booster Vaccine against Covid-19
The safety and immunogenicity of the bivalent omicron-containing mRNA-1273.214 booster vaccine are not known.
A Bivalent Omicron-Containing Booster Vaccine against Covid-19 | NEJM
Â
METHODS
In this ongoing, phase 2â [...]
Vacunas 07 / 11 / 2022
Evaluation of mRNA-1273 Vaccine in Children 6 Months to 5 Years of Age
Adverse events were mainly low-grade and transient, and no new safety concerns were identified. At day 57, neutralizing antibody geometric mean concentrations were 1410 (95% confidence interval [CI], 1272 to 1563) amo [...]
Vacunas 17 / 10 / 2022
Long-term neurologic outcomes of COVID-19
In the postacute phase of COVID-19, there was increased risk of an array of incident neurologic sequelae including ischemic and hemorrhagic stroke, cognition and memory disorders, peripheral nervous system disorders, epi [...]
Vacunas 12 / 10 / 2022
Health outcomes and economic burden of hospitalized COVID-19 patientes in the United States
This study summarizes the severe health outcomes and substantial hospital costs of hospitalized COVID-19 patients in the US. The findings support the urgent need for rapid implementation of effective interventions, inclu [...]
Vacunas 16 / 09 / 2022
Central nervous system outcomes of COVID-19
Although COVID-19, the disease caused by the SARS-CoV-2 virus, is primarily a respiratory disease, an increasing number of neurologic symptoms have been reported. Some of these symptoms, such as loss of smell or taste, a [...]
Vacunas 16 / 09 / 2022
Pathological sequelae of long-haul COVID
The world continues to contend with successive waves of coronavirus disease 2019 (COVID-19), fueled by the emergence of viral variants. At the same time, persistent, prolonged and often debilitating sequelae are increasi [...]
Vacunas 12 / 09 / 2022
Alteración Pancreática del Sars-CoV-2 : diabetes e impacto en las células beta
El SARS-CoV-2 es capaz de infectar a las células beta pancreáticas productoras de insulina, lo que puede ayudar a comprender por qué los pacientes con COVID-19 experimentan en algunos casos sÃntomas relacionados con [...]
Vacunas 12 / 09 / 2022
La afectación del SARS-CoV-2 en el nervio vago podrÃa ser una causa potencial de las manifestaciones de la COVID-19 persistente
Los principales factores de riesgo para desarrollar COVID-19 persistente: "En primer lugar, el sexo, la edad e incluso el número de sÃntomas. AsÃ, las mujeres y las personas entre 40 y 54 años muestran más probabili [...]
Vacunas 19 / 08 / 2022
Global Impact  f the first year of COVID -19 Vaccination: a Mathematical Modelling study
Vaccinations prevented 14·4 million (95% credible interval [Crl] 13·7–15·9) deaths from COVID-19 in 185 countries and territories between Dec 8, 2020, and Dec 8, 2021. This estimate rose to 19·8 million (95% Crl 19 [...]